AstraZeneca expects continued profit growth in 2024, driven by robust sales of its cancer therapeutics, which are helping offset revenue losses from the impending patent expiry of its blockbuster diabetes drug. In an interview with Bloomberg's *The Opening Trade* on February 10, CEO Pascal Soriot emphasized the company's strategic focus on oncology while navigating the competitive pharmaceutical landscape. The diabetes drug, a major revenue contributor, will lose exclusivity in key markets, prompting AstraZeneca to prioritize its pipeline of next-generation cancer treatments to maintain financial momentum.

The shift toward oncology reflects broader industry trends, as generics increasingly erode profits from established drugs. AstraZeneca's pipeline includes experimental therapies targeting solid tumors and immunotherapy combinations, which the CEO described as "critical to sustaining long-term growth." Analysts note that the firm's ability to scale these innovations will determine its market position amid rising competition from rivals like Roche and Merck.

While the diabetes drug's patent expiry is expected to reduce annual revenue by $1.2 billion, Soriot remains optimistic, citing resilient demand for the company's cancer portfolio. AstraZeneca's shares have surged 18% this year on confidence in its R&D pipeline, though risks persist around clinical trial outcomes and regulatory approvals. The company's strategy to reinvest savings from the diabetes drug's generic transition into oncology R&D underscores its pivot toward high-growth therapeutic areas.

This realignment highlights the fragility of relying on blockbuster drugs with finite patent protections. AstraZeneca's success hinges on accelerating its oncology pipeline, with phase III trials for its next-generation cancer drugs slated for 2025. Investors are closely monitoring whether the company can convert preclinical promise into marketable treatments, ensuring profitability beyond the diabetes drug's decline.